Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Assets: 2010-2025

Historic Assets for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Sep 2025 value amounting to $1.1 billion.

  • Catalyst Pharmaceuticals' Assets rose 36.22% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 36.22%. This contributed to the annual value of $851.4 million for FY2024, which is 81.11% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Assets of $1.1 billion as of Q3 2025, which was up 8.20% from $971.9 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Assets ranged from a high of $1.1 billion in Q3 2025 and a low of $197.2 million during Q1 2021.
  • In the last 3 years, Catalyst Pharmaceuticals' Assets had a median value of $706.4 million in 2024 and averaged $694.8 million.
  • Data for Catalyst Pharmaceuticals' Assets shows a peak YoY surged of 86.83% (in 2024) over the last 5 years.
  • Catalyst Pharmaceuticals' Assets (Quarterly) stood at $237.8 million in 2021, then spiked by 57.97% to $375.6 million in 2022, then rose by 25.15% to $470.1 million in 2023, then soared by 81.11% to $851.4 million in 2024, then skyrocketed by 36.22% to $1.1 billion in 2025.
  • Its Assets stands at $1.1 billion for Q3 2025, versus $971.9 million for Q2 2025 and $908.9 million for Q1 2025.